Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of topical OXT-328 for neuropathic conditions
2026-527437-55-00Phase 2Authorised
- Sponsor
- Jcare Pharmaceuticals LLC
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of phosphosulindac in chemotherapy-induced peripheral neuropathy (CIPN), diabetic polyneuropathy (DPN) and cervical radiculopathy (3 cohorts), sponsored by Jcare Pharmaceuticals LLC. Primary endpoint: Change in GS-NRS from pre-dose to 2 hours after the first Day 1 applications, pooled across cohorts. Planned start Oct 2026; status: authorised.
02
Drugs
phosphosulindac
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)diabetic polyneuropathy (DPN)cervical radiculopathy
Beyond the preview
Go deeper on 2026-527437-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527437-55-00.